Figure 1
From: The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response
Summary of the main bevacizumab-mediated immunomodulatory events. VEGF-A inhibition by bevacizumab has been correlated with a number of immunological events. Bevacizumab is able to promote DCs maturation, as well as to improve DCs’ amount and function. In addition, this monoclonal antibody can improve both CD8+ CTLs and CD4+ T helper 1 cells (Th1) immune response in tumor surveillance. In addition, as part of the immunomodulatory events induced by VEGFA neutralization, bevacizumab leads to a significant inhibition of MDSCs and TAM accumulation in tumor microenvironment. Finally, the expression levels of several proangiogenic and proinflammatory factors appear strongly reduced upon bevacizumab treatment. CTLs, cytotoxic T cells; DCs, dendritic cells; MDSCs, myeloid-derived suppressor cells; TAM, tumor-associated macrophages; VEGF-A, vascular endothelial growth factor A
